Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Swiss National Bank

Swiss National Bank cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 497,900 shares of the biotechnology company's stock after selling 7,000 shares during the quarter. Swiss National Bank owned approximately 0.18% of Exelixis worth $18,382,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EXEL. Fuller & Thaler Asset Management Inc. grew its position in shares of Exelixis by 10.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock valued at $254,110,000 after acquiring an additional 708,312 shares during the period. AQR Capital Management LLC grew its position in shares of Exelixis by 25.7% during the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock valued at $132,101,000 after acquiring an additional 810,857 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Exelixis by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company's stock valued at $122,626,000 after acquiring an additional 69,054 shares during the period. FMR LLC grew its position in shares of Exelixis by 19.7% during the 4th quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock valued at $98,155,000 after acquiring an additional 485,527 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in shares of Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock valued at $82,730,000 after acquiring an additional 1,907,167 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Down 0.4%

EXEL stock traded down $0.16 during mid-day trading on Friday, hitting $38.31. 2,370,582 shares of the company were exchanged, compared to its average volume of 3,938,011. The firm has a market capitalization of $10.31 billion, a P/E ratio of 18.42, a PEG ratio of 0.80 and a beta of 0.29. The business has a fifty day simple moving average of $41.96 and a 200-day simple moving average of $39.15. Exelixis, Inc. has a 12-month low of $25.12 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. Exelixis's revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.84 earnings per share. Research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling at Exelixis

In related news, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director owned 358,882 shares of the company's stock, valued at $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 34,387 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $44.06, for a total transaction of $1,515,091.22. Following the completion of the sale, the executive vice president directly owned 412,072 shares in the company, valued at approximately $18,155,892.32. This trade represents a 7.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,304 shares of company stock worth $2,846,164 over the last ninety days. Company insiders own 2.82% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Truist Financial reduced their target price on shares of Exelixis from $56.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th. Wall Street Zen downgraded shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 2nd. Benchmark restated a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Bank of America upped their price target on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Finally, HC Wainwright set a $46.00 price target on shares of Exelixis and gave the company a "buy" rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $44.06.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.